New Gene Therapy Offers Potential Cure for Sickle Cell Disease
A new gene therapy, approved in December 2023, is offering a potential cure for sickle cell disease, with patients treated at Children's Hospital in St. Louis reporting significant improvements and a restored quality of life. The treatment involves genetically modifying…
Champaign Urbana & Springfield Decatur, IL, September 18, 2026 —
A novel gene therapy, which received regulatory approval in December 2023, is showing promise as a potential cure for sickle cell disease. Patients undergoing this treatment at Children’s Hospital in St. Louis have reported substantial improvements in their health and a restoration of their quality of life.
Sickle cell disease is a genetic disorder characterized by abnormal hemoglobin, leading to misshapen red blood cells that can block blood flow and cause severe pain, organ damage, and other complications. The new treatment aims to address the root cause of the disease by modifying the patient’s own cells.
The therapeutic process involves several key steps. Initially, a patient’s stem cells are genetically modified outside the body. This is followed by a course of chemotherapy, which prepares the body by eliminating existing sickle-shaped cells. Finally, the genetically modified cells are reinfused into the patient. The goal of this reinfusion is for the modified cells to produce healthy hemoglobin, thereby helping to eliminate sickle cells from circulation.
According to reports, patients treated with this therapy at Children’s Hospital in St. Louis have experienced significant positive outcomes. These improvements are said to have led to a restored quality of life for those affected by the debilitating effects of sickle cell disease. Specific details regarding the number of patients treated, the exact nature of the genetic modifications, the specific chemotherapy agents used, or the precise metrics for “significant improvements” were not provided.
The approval of this gene therapy in December 2023 marks a significant advancement in the treatment landscape for sickle cell disease. While the long-term effects and broader applicability are still under observation, the initial results from patient treatments in St. Louis suggest a promising new avenue for managing and potentially curing the condition.
Story summarized from the original created by Caroline Hecker, LeAnne Gendreau on www.wandtv.com, see more information here.
Media gallery
